FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Clinical trials for FOCAL SEGMENTAL GLOMERULOSCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new FOCAL SEGMENTAL GLOMERULOSCLEROSIS trials appear
Sign up with your email to follow new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New kidney drug shows promise in FSGS trial
Disease control CompletedThis Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise for rare kidney disease in early trial
Disease control CompletedThis study tested a new medicine, BI 764198, in 67 adults with a kidney disease called FSGS. Participants took different doses of the medicine or a placebo daily for 12 weeks. The goal was to see if the medicine could reduce protein in the urine, a sign of better kidney health. T…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kidney patients: experimental drug targets protein leak
Disease control CompletedThis study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could r…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Preemptive drug combo may shield new kidneys from FSGS return
Prevention CompletedThis study tested whether giving the drug rituximab along with a blood-filtering procedure called plasmapheresis right before a kidney transplant could prevent focal segmental glomerulosclerosis (FSGS) from recurring. The trial enrolled 21 children and adults with FSGS who were g…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: University of Minnesota • Aim: Prevention
Last updated Jun 26, 2026 16:28 UTC
-
Scientists dig into mysterious kidney scarring
Knowledge-focused CompletedThis completed study looked at why some people develop scarring in their kidneys, including rare diseases like FSGS and a mysterious form of chronic kidney disease affecting farm workers. Researchers collected blood, urine, and kidney tissue from 537 participants to better unders…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Gene hunt for kidney disease FSGS aims to explain racial disparities
Knowledge-focused CompletedThis study searched for genetic factors that may cause focal segmental glomerulosclerosis (FSGS), a kidney disease that can lead to kidney failure. Researchers compared DNA from 616 people, including African-Americans with FSGS, African-Americans with HIV but no FSGS, and non-Afr…
Matched conditions: FOCAL SEGMENTAL GLOMERULOSCLEROSIS
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC